FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.
What happened
FDA inspected Apotex Inc.'s drug manufacturing facility at 380 Elgin Mills Road East, Richmond Hill, Ontario, from April 28 to May 9, 2025. Investigators found that the company repeatedly re-ran leak tests until they passed instead of investigating failures, filled sterile products on equipment with unresolved integrity problems, and had deteriorated isolator gloves and gaskets, tape on covers, and inadequate environmental monitoring. After the inspection Apotex paused U.S. production of certain sterile products and recalled three ophthalmic solutions (azelastine, ketorolac, brimonidine/timolol) and one lot of lacosamide oral solution.
What FDA found
The company did not properly investigate failed leak tests on its aseptic filling equipment, re-testing until results passed instead of finding the root cause.
21 CFR 211.192It did not fully investigate container-closure failures, including a stability sample that leaked and corroded its cap liner, and took no market action at the time.
21 CFR 211.192It did not investigate repeated excessive weight loss in stability samples of multiple products.
21 CFR 211.192Aseptic areas and isolator equipment were not adequately cleaned, decontaminated and maintained, with discoloration, deteriorated gaskets, and tape used on covers.
21 CFR 211.113(b) & 211.42(c)(10)Environmental monitoring was inadequate because critical aseptic areas lacked continuous particle monitoring and relied on a single probe facing away from open processing.
21 CFR 211.113(b)Equipment used for spray drug products was shedding white particles onto surfaces, and an available design upgrade was not installed for nearly a year.
21 CFR 211.67(a)
What FDA wants
FDA wants an independent assessment and remediation plan for the deviation investigation and CAPA systems, a contamination-hazard risk assessment of aseptic operations with a maintenance and oversight plan, a retrospective cleaning assessment, and a visual inspection remediation plan. The company must reply in writing within 15 working days.
Who should pay attention
- brands and repackagers that buy finished sterile or ophthalmic products from this contract manufacturer
- quality teams running aseptic filling operations with isolators or barrier systems
- companies relying on container-closure integrity and leak-test data from suppliers
This is a summary. Read the original letter on fda.gov.